Last reviewed · How we verify
NCT00246493
Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)
trial in Atherosclerosis in 495 participants. Terminated before completion.
Quick facts
| Lead sponsor | National Institute on Aging (NIA) |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 495 |
| Start date | 22 June 2004 |
| Estimated completion | 1 November 2017 |
| Sites | 2 locations across United States |
Conditions studied
- Atherosclerosis — all drugs for Atherosclerosis →
- Cardiovascular Disease — all drugs for Cardiovascular Disease →
- Vascular Diseases — all drugs for Vascular Diseases →
Sponsor
National Institute on Aging (NIA)
Who can join
30 and older, any sex, with Atherosclerosis or Cardiovascular Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The prevalence, incidence, and severity of atherosclerotic disease all markedly increase with age. Basic experimental and observational data demonstrate that aging magnifies the pathologic and clinical consequences of established risk factors and is the most potent individual risk factor for coronary atherosclerosis and for adverse outcomes following an ischemic event. These findings suggest that normal aging alters the vascular substrate so as to promote the development and progression of atherosclerosis. The age-associated changes in vascular structure and function include an increase in central vascular stiffness, intimal proliferation, and endothelial dysfunction. The major hypothesis is that the above alterations in vascular substrate (i.e. vascular age) are an important determinant of the age associated increased likelihood for the development and progression of coronary atherosclerotic disease. This program will non-invasively characterize vascular age and atherosclerotic burden in BLSA participants and individuals with successful aging, i.e. those with no or minimal evidence of coronary atherosclerotic disease, and those with premature, clinically evident coronary artery disease. It will repeat measures of vascular age and atherosclerotic burden three years after the first assessment. By examining the impact of vascular age on the initial extent and the progression of atherosclerotic burden over a two to three-year period, it will test the hypothesis that vascular age is an important determinant of the ageassociated increase in atherosclerotic disease....
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00246493
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atherosclerosis
Currently open trials in the same condition.
- NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT06788431 — A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary · EARLY_PHASE1 · recruiting
- NCT06676046 — Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions · recruiting
- NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting
Other National Institute on Aging (NIA) trials
Trials by the same sponsor.
- NCT06274749 — Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Mask · NA · recruiting
- NCT07099053 — Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging · recruiting
- NCT06912724 — Pediatric Neuroimaging · recruiting
- NCT06273917 — Deprescribing Potentially Inappropriate Medications in the Emergency Department for Persons Living With Dementia · NA · completed
- NCT06269653 — Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00246493 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute on Aging (NIA)
- Last refreshed: 9 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00246493.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing